Corbus Pharmaceuticals Advances Obesity Treatment with CRB-913

The latest announcement is out from Corbus Pharmaceuticals ( (CRBP) ).

On December 11, 2025, Corbus Pharmaceuticals announced the completion of its Phase 1a study of CRB-913, an oral CB1 inverse agonist for obesity management, and the initiation of a Phase 1b study expected to conclude in summer 2026. The Phase 1a study demonstrated that CRB-913 was safe, well-tolerated, and effective in promoting weight loss, with no serious adverse events reported, marking a significant step forward in Corbus’ obesity treatment research.

The most recent analyst rating on (CRBP) stock is a Buy with a $39.00 price target. To see the full list of analyst forecasts on Corbus Pharmaceuticals stock, see the CRBP Stock Forecast page.

Spark’s Take on CRBP Stock

According to Spark, TipRanks’ AI Analyst, CRBP is a Neutral.

Corbus Pharmaceuticals’ overall stock score is driven by severe financial challenges, including no recent revenue and high net losses, which significantly weigh down its score. However, technical indicators suggest some short-term positive momentum. The promising Phase 1 trial results provide a potential catalyst in the biotechnology field, offering some positive outlook despite the current financial difficulties.

To see Spark’s full report on CRBP stock, click here.

More about Corbus Pharmaceuticals

Corbus Pharmaceuticals Holdings, Inc. is a clinical-stage company focused on oncology and obesity, headquartered in Norwood, Massachusetts. The company is committed to innovative scientific approaches targeting well-understood biological pathways, with a pipeline that includes CRB-701, CRB-601, and CRB-913, the latter being a CB1 inverse agonist for obesity treatment.

Average Trading Volume: 372,350

Technical Sentiment Signal: Sell

Current Market Cap: $177.3M

Learn more about CRBP stock on TipRanks’ Stock Analysis page.